DCGI gives nod to Intranasal C-19 booster dose

The nasal vaccine can be taken six months after the second dose. As this is non-invasive and needle-free, it becomes easy to administer.

The Health Master

November 26, 2022

297

DCGI CDSCO Regulator Drugs Controller General India — DCGI

Last Updated on October 15, 2024 by The Health Master

New Delhi: The Drugs Controller General of India (DCGI) has given approval to vaccine manufacturer Bharat Biotech’s intranasal “Five Arms” C-19 booster dose for restricted use.

A source said that the emergency use authorization (EUA) has been given to the nasal vaccine iNCOVACC for restricted emergency use as the third dose for adults, irrespective of whether they have received Covaxin or Covishield vaccine doses.

Click for more articles on DCGI

As per the vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa.

Thus, intranasal immunization of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection, and transmission.

The nasal vaccine can be taken six months after the second dose. As this is non-invasive and needle-free, it becomes easy to administer.

Bharat Biotech claimed that the intranasal vaccine stimulates a broad immune response. It is likely to block both the infection and transmission of C-19.

Must read

Also read

USFDA issues Form 483 with 8 observations to Lupin

Drug recall: FDA issues nationwide recall for Ferric Carboxymaltose

Govt issues draft notification to amend NDCTR, 2019

Haryana: Sathi app launched to check Drugs abuse

CDSCO approves 4 more Medical Device Testing Labs (MDTL)

Antitrust litigation filed against Dr Reddy’s Lab and others